Program Code: SCF-DBI-PCICU-TX-0001**
Operational Window: Pre-Transplant Evaluation → Immediate Post-Transplant Recovery → Lifelong Surveillance
Primary Objective: Preserve graft function, maintain immunologic self-tolerance, prevent rejection-mediated biologic intelligence disruption, optimize recovery, and maximize long-term allograft adaptation.
SECTION 7.1
CLINICAL POSITIONING
Traditional Cardiac Transplant Model
Focuses on:
Graft survival
Rejection prevention
Immunosuppression
Infection prevention
Long-term survival
SCF-DBI Cardiac Transplant Model
Cardiac transplantation is viewed as:
Controlled Biological Integration Process
requiring simultaneous preservation of:
Graft Intelligence
Host Intelligence
Endothelial Intelligence
Neuroimmune Intelligence
Recovery Intelligence
Core Principle
Successful transplantation is not merely graft acceptance.
It is the establishment of stable biologic coexistence between host and allograft.
SECTION 7.2
TRANSPLANT BIOLOGICAL INTELLIGENCE MODEL
Phase 1
Pre-Transplant Instability
Characteristics:
Advanced heart failure
Reduced recovery reserve
Neurocardiac adaptation failure
Phase 2
Early Graft Integration
Characteristics:
Hemodynamic stabilization
Immune activation risk
Endothelial vulnerability
Phase 3
Adaptive Tolerance Formation
Characteristics:
Recovery progression
Self-tolerance development
Functional adaptation
Phase 4
Long-Term Integration
Characteristics:
Stable graft function
Preserved adaptation
Long-term resilience
SECTION 7.3
IMMEDIATE POST-TRANSPLANT CRITICAL CARE SOP
First 24-Hour Objectives
Optimize graft perfusion
Prevent primary graft dysfunction
Preserve cerebral oxygenation
Maintain endothelial stability
Initiate recovery intelligence surveillance
Immediate Monitoring
Cardiac output
Lactate
NIRS
Mixed venous oxygen saturation
Echocardiography
ANMS
NCRS
SECTION 7.4
PRIMARY GRAFT DYSFUNCTION (PGD) MANAGEMENT FRAMEWORK
Clinical Positioning
PGD represents:
Acute Allograft Adaptation Failure Syndrome
Risk Factors
Donor ischemic injury
Reperfusion injury
Pulmonary hypertension
Recipient instability
Endothelial dysfunction
Severity Classification
Grade I
Mild dysfunction
Grade II
Moderate dysfunction
Grade III
Severe dysfunction
Grade IV
Critical dysfunction
Mechanical support consideration
Monitoring Variables
Ventricular performance
Lactate
NIRS
NCRS
EII
SECTION 7.5
ACUTE CELLULAR REJECTION FRAMEWORK
Clinical Positioning
Acute cellular rejection represents:
Adaptive Immune-Mediated Graft Injury
Surveillance Variables
Echocardiography
Biomarkers
Hemodynamic status
Recovery trajectory
STRI
Rejection Classification
Grade A
Subclinical
Grade B
Mild
Grade C
Moderate
Grade D
Severe
SECTION 7.6
ANTIBODY-MEDIATED REJECTION (AMR) FRAMEWORK
Clinical Positioning
AMR represents:
Humoral Immune Adaptation Failure
Major Threats
Endothelial injury
Microvascular dysfunction
Graft ischemia
Progressive graft failure
Monitoring Domains
Donor-specific antibodies
Endothelial markers
Perfusion status
EII
ANMS
SECTION 7.7
TRANSPLANT SELF-TOLERANCE PRESERVATION PROGRAM (TSTPP)
Strategic Objective
Promote immune regulation while maintaining host defense.
Core Domains
Domain 1
Immune Competence Preservation
Domain 2
Tolerance Promotion
Domain 3
Inflammation Control
Domain 4
Recovery Preservation
Domain 5
Endothelial Protection
Primary Output
Transplant Self-Tolerance Recovery Index (T-STRI)
SECTION 7.8
NEUROIMMUNE TRANSPLANT SURVEILLANCE ENGINE
Purpose
Identify rejection and immune dysregulation before clinical deterioration.
Surveillance Domains
Cellular immunity
Humoral immunity
Endothelial adaptation
Recovery biology
Monitoring Variables
CRP
Cytokine burden
Lymphocyte profiles
T-STRI
ANMS
SECTION 7.9
IMMUNOSUPPRESSION INTELLIGENCE FRAMEWORK
Strategic Goal
Maintain optimal balance between:
Rejection prevention
and
Infection prevention
Monitoring Domains
Drug exposure burden
Immune suppression burden
Recovery burden
Developmental burden
Output
Immunologic Adaptation Index (IAI)
SECTION 7.10
RHENOVA TRANSPLANT RECOVERY PLATFORM
Strategic Objective
Begin long-term graft preservation during the first postoperative day.
Recovery Domain 1
Graft Recovery
Recovery Domain 2
Endothelial Recovery
Recovery Domain 3
Immune Recovery
Recovery Domain 4
Neurodevelopmental Recovery
Recovery Domain 5
Functional Recovery
SECTION 7.11
CARDIAC ALLOGRAFT INTELLIGENCE PROGRAM
Purpose
Continuously evaluate graft adaptation.
Domain A
Hemodynamic Intelligence
Cardiac output
Ventricular function
Oxygen delivery
Domain B
Endothelial Intelligence
EII
Perfusion
Microvascular adaptation
Domain C
Immune Intelligence
T-STRI
IAI
Rejection burden
Output
Cardiac Allograft Intelligence Score (CAIS)
SECTION 7.12
TRANSPLANT ESCALATION MATRIX
Level 1
Enhanced Monitoring
Triggers:
Biomarker abnormalities
Recovery slowing
Level 2
Focused Intervention
Triggers:
T-STRI decline >15%
EII decline >15%
Level 3
Multidisciplinary Escalation
Triggers:
Suspected rejection
Progressive graft dysfunction
Level 4
Advanced Rescue Activation
Triggers:
Severe rejection
Significant ventricular dysfunction
Level 5
Transplant Rescue Activation
Triggers:
ANMS <40
Severe graft failure
Mechanical support consideration
SECTION 7.13
LONGITUDINAL CARDIAC ALLOGRAFT SURVEILLANCE
Monitoring Timeline
ICU Discharge
↓
30 Days
↓
90 Days
↓
6 Months
↓
12 Months
↓
Annual Surveillance
Surveillance Domains
Graft function
Rejection burden
Growth
Neurodevelopment
Exercise tolerance
Quality of life
SECTION 7.14
TRANSPLANT RECOVERY INTELLIGENCE PROGRAM
Long-Term Objectives
Stable graft adaptation
Preserved neurodevelopment
Preserved immune competence
Preserved endothelial integrity
Preserved functional independence
Recovery Monitoring
CAIS
T-STRI
ANMS
NCRS
EII
SECTION 7.15
TRANSPLANT SUCCESS ENDPOINTS
Clinical
Stable graft function
No severe rejection
Reduced rehospitalization
Functional
Normal activity participation
Educational participation
Psychosocial adaptation
Biological Intelligence
ANMS >80
CAIS >80
T-STRI >80
NCRS >80
EII >80
Long-term adaptive stability
PAGE 7 COMPLETION
Next Page (Page 8):